| Literature DB >> 20822912 |
Eun Ju Kim1, Dona C Love, Etzer Darout, Mohannad Abdo, Brian Rempel, Stephen G Withers, Paul R Rablen, John A Hanover, Spencer Knapp.
Abstract
The title compound, which differs from the powerful O-GlcNAcase (OGA) inhibitor GlcNAc-thiazoline only at the chalcogen atom (Se for S), is a much weaker inhibitor in a direct OGA assay. In human cells, however, the selenazoline shows comparable ability to induce hyper-O-GlcNAc-ylation, and the two show similar reduction of insulin-stimulated translocation of glucose transporter 4 in differentiated 3T3 adipocytes.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20822912 PMCID： PMC4210863 DOI： 10.1016/j.bmc.2010.08.010
Source DB: PubMed Journal: Bioorg Med Chem ISSN： 0968-0896 Impact factor: 3.641